Demonstration of anti‐TSH antibody in TSH binding inhibitory immunoglobulin‐positive sera of patients with Graves’ disease

Abstract

The presence of anti-bTSH antibody in TBII-positive serum of high titre means that TBII-positive sera cannot rule out the absence of anti-bTSH. Thus, determination of 125I-bTSH binding with test serum in TSH receptor assays is necessary to determine the precise TBII activity and to detect anti-bTSH antibody.

Neutralization and purification of thyroid stimulating antibody (TSAb) and thyroid blocking antibody (TBAb) by heterophilic antibody to animal IgG in Graves' disease

“…One possibility is epitope heterogeneity (such as dog, bovine, porcine etc) of heterophilic antibodies. Previously we observed similar phenomenon: the existence of anti-bTSH Ab in LATS-positive and TBIIpositive serum of Graves' disease [29][30][31]. Further studies are necessary to resolve these phenomena.…”

“…We reported the existence of anti-bTSH Ab in 2 Graves' patients (one is LATS positive) measured by TBII assay kit using 125 I-bTSH (1 st generation assay kit). However, this anti-bTSH Ab was Ab to mammalian TSH (dog, bovine, porcine, rabbit, rat, guinea-pig, whale) and not to human TSH [29][30][31]. This anti-bTSH Ab is found about <1% of Graves' disease.…”

B Cells in Autoimmune Diseases

“…Inhibitory autoantibodies are also found in Myasthenia gravis, where autoantibodies bind to the nicotine ACh receptors (AChRs) and block neurotransmission at the neuromuscular junction, inducing symptoms such as muscle weakness and fatigue [19], and in multifocal motor neuropathy, where autoantibodies bind to the ganglioside GM1 and cause motor neuropathy with conduction block at multiple sites [20]. Other autoantibodies can bind receptor ligands, preventing their binding to the receptor, as seen in Graves' disease with anti-TSH autoantibodies [21]. Table 1 summarizes other examples of receptor autoantibodies, their targets, pathogenic mechanisms, and associated diseases.…”

A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves’ disease

“…In addition, we tested the biological activity of TBII in a subgroup of patients with a history of GD who spontaneously developed hypothyroidism. The demonstration of TBAb may add to the diagnosis of GD‐induced hypothyroidism 11,16,17 …”